{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:32:02Z","timestamp":1791977522947,"version":"4.4.0"},"reference-count":45,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T00:00:00Z","timestamp":1430697600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:p>Leishmaniasis is a protozoan infection native to various countries, including those in South America and Southeast Asia. Although the incidence of leishmaniasis is low in the United States, it is an important cause of infection in individuals traveling to endemic areas. Various treatment modalities are available, depending on their availability in the geographic region. In the United States, the treatment of choice is considered to be liposomal amphotericin, although other therapies have been explored. In 2014, miltefosine became the first orally available medication approved for the treatment of leishmaniasis in the United States. Based on available data, miltefosine is a first\u2010line option for the treatment of leishmaniasis. Miltefosine is equally efficacious to and may be as tolerable as liposomal amphotericin B. The most common adverse effects of miltefosine are vomiting, diarrhea, and transient liver enzyme level elevation. Miltefosine has not been readily available in the United States due to marketing delays and is expected to become available later this year. In the meantime, the drug may be obtained through the Centers for Disease Control and Prevention expanded\u2010access investigational new drug protocol.<\/jats:p>","DOI":"10.1002\/phar.1585","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T04:48:08Z","timestamp":1430714888000},"page":"536-545","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacotherapy for Leishmaniasis in the United States: Focus on Miltefosine"],"prefix":"10.1002","volume":"35","author":[{"given":"Niyati H.","family":"Vakil","sequence":"first","affiliation":[{"name":"Department of Pharmacy Cedars\u2010Sinai Medical Center Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Fujinami","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cedars\u2010Sinai Medical Center Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Alexian Brothers Health System Elk Grove Village Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67629-5"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2010.06.019"},{"key":"e_1_2_7_4_1","unstructured":"Centers for Disease Control and Prevention. Parasites\u2010Leishmaniasis: Epidemiology and Risk Factors. Available fromhttp:\/\/www.cdc.gov\/parasites\/leishmaniasis\/epi.html. Accessed June 27 2014."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)10178-2"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4269\/ajtmh.1995.53.73","article-title":"Leishmaniasis in Texas; prevalence and seasonal transmission of Leishmania mexicanain Neotoma micropus","volume":"53","author":"Kerr SF","year":"1995","journal-title":"Am J Trop Med Hyg"},{"key":"e_1_2_7_7_1","unstructured":"World Health Organization. Leishmaniasis. Available fromwww.who.int\/mediacentre\/factsheets\/fs375\/en\/. Accessed March 6 2015."},{"key":"e_1_2_7_8_1","first-page":"3463","volume-title":"Principles and practice of infectious diseases","author":"Magill AJ","year":"2010"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2007.00311.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S44267"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000168337"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP70065"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1051\/parasite\/2014014"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)80121-6"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.03851.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2012.03.001"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1995-7645(12)60084-4"},{"key":"e_1_2_7_18_1","unstructured":"Centers for Disease Control and Prevention.Parasites\u2010 Leishmaniasis: Resources for Health Professionals. Available fromhttp:\/\/www.cdc.gov\/parasites\/leishmaniasis\/health_professionals\/. Accessed June 21 2014."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2006.09.004"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-13-58"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/341406"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2012.748036"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70296-6"},{"key":"e_1_2_7_24_1","volume-title":"Amphotericin B deoxycholate (Fungizone)","author":"X\u2010Gen Pharmaceuticals, Inc","year":"2010"},{"key":"e_1_2_7_25_1","volume-title":"Amphotericin B liposomal (Ambisome)","author":"Gilead Sciences","year":"2012"},{"key":"e_1_2_7_26_1","volume-title":"Amphotericin B lipid complex (Abelcet)","author":"Sigma\u2010tau Pharmaceuticals, Inc","year":"2013"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/380971"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.752"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011882"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir496"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.01133.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890310070009"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20104362.1991.tb04878.x"},{"key":"e_1_2_7_34_1","first-page":"519","article-title":"Itraconazole and leishmaniasis: a randomized double\u2010blind trial in cutaneous disease","volume":"30","author":"Dogra J","year":"1991","journal-title":"Int J Dermatol"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01498-10"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-6851(00)00278-4"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90543-0"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.8.1630"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021556"},{"key":"e_1_2_7_40_1","volume-title":"DRUGDEX system (micromedex solutions)","author":"Miltefosine","year":"2015"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1086\/505217"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.02.022"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2008.78.210"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1086\/510588"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks275"},{"issue":"33","key":"e_1_2_7_46_1","first-page":"666","article-title":"Investigational drug available directly from CDC for the treatment of infections with free\u2010living amebae","volume":"62","author":"Cope JR","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1585","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1585","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:25:27Z","timestamp":1761045927000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1002\/phar.1585"],"URL":"https:\/\/doi.org\/10.1002\/phar.1585","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"2015-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}